[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336557-105":59,"doc-detail-336557-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","cardiovascular-mortality-in-people-with-cancer-compared-to-the-general-population-a-systematic-review-and-metaanalysis","Cardiovascular mortality in people with cancer compared to the general population - A systematic review and metaanalysis","","Background: Cardiovascular disease (CVD) is the leading cause of non-cancer death among cancer survivors, yet CVD risk differs across cancer types. Objectives: Synthesize evidence on patterns and magnitude of CVD mortality risk. Methods: Systematic search of Medline (OVID), CINAHL, and Scopus (01-Jan-2000 to 16-Jul-2023); meta-analysis of standardised mortality ratios (SMRs) using a random-effects model. Results: 136 studies from 16 countries; pooled SMR 1.55 (95% CI 1.40–1.72). Conclusions: Increased premature CVD mortality persists, varying by cancer and CVD condition.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cardiovascular-mortality-in-people-with-cancer-compared-to-the-general-population-a-systematic-review-and-metaanalysis/336557/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cardiovascular-mortality-in-people-with-cancer-compared-to-the-general-population-a-systematic-review-and-metaanalysis/336557.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What question does the systematic review address?","Question",{"text":113,"@type":114},"It compares CVD mortality risk between people with cancer and the general population, and evaluates whether risk differs by cancer type.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were eligible studies selected?",{"text":118,"@type":114},"Eligible studies included all ages with a cancer diagnosis and reported CVD mortality data as standardised mortality ratios (SMRs), were peer-reviewed, in English, and published since 2000.",{"name":120,"@type":111,"acceptedAnswer":121},"What do the meta-analysis findings show about CVD mortality in cancer survivors?",{"text":122,"@type":114},"Cancer survivors have an increased risk of CVD death versus the general population, with pooled SMR=1.55 (95% CI 1.40–1.72). Risk varies by both CVD condition and cancer type.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},336557,1790026933,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","DOI: 10. 1002/cam4 .70057  \nRESEAR CH ARTICLE  \nCardiovascular mortality in people with cancer compared to the general population: A systematic review and metaanalysis  \nHuah Shin Ng1,2  | Rosie Meng1 | Tania S. Marin1 | Raechel A. Damarell3 | Elizabeth Buckley1 | Joseph B. Selvanayagam1,4 | Bogda Koczwara1,5   \n1Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia 2SA Pharmacy, SA Health, Adelaide, South Australia, Australia  \n3Research Centre for Palliative  \nCare, Death and Dying, College of Nursing and Health Sciences, Flinders University, Adelaide, South Australia, Australia  \n4Department of Cardiovascular Medicine, Flinders Medical Centre, Adelaide, South Australia, Australia 5Department of Medical Oncology, Flinders Medical Centre, Adelaide, South Australia, Australia  \nCorrespondence  \nHuah Shin Ng, College of Medicine and Public Health, Flinders University, Sturt Road, Bedford Park, SA 5042, Australia. [Email:](Email: huahshin.ng@flinders.edu.au)[ huahshin.ng@flinders.edu.au](Email: huahshin.ng@flinders.edu.au)  \nAbstract  \nBackground: Cardiovascular disease (CVD) is the leading cause of non-cancer death in cancer survivors, but the risk of CVD varies between cancers. Objectives: To synthesise available evidence on patterns and magnitude ofCVD mortality risk.  \nMethods: A systematic search of Medline (OVID), CINAHLandScopus databases from 01-January-2000 to 16-July-2023 of studies of people with cancer, reporting CVD mortality in cancer population compared with a reference population (e.g. general population) as standardised mortality ratios (SMR) . Meta-analysis of SMRs across cancer and CVD types were pooled using a random-effects model to allow for heterogeneity of the true effect size across studies.  \nResults: We identified 136 studies from 16 countries. Sample sizes ranged from 157 to 7,529,481. The majority (n = 98; 72%) were conducted in the United States, followed by Europe (n = 22; 16%) . The most common cancers studied were gastrointestinal (n = 34 studies), haematological (n = 31) and breast (n = 29) . A total of 876 CVD SMRs were extracted across diverse CVD conditions. Of those, the majority (535; 61%) indicated an increased risk of CVD death (SMR >1), 109 (12%) a lower risk ofCVD death (SMR \u003C1) and 232 (27%) an equivalent risk (95% CI of SMR included 1) compared to the general population. The meta-analysis of all reported SMRs showed an increased risk of CVD death (SMR = 1.55, 95% CI = 1.40–1.72) in cancer survivors compared with the general population. The SMR varied between CVD conditions and ranged from 1.36 (95% CI = 1.29–1.44) for heart diseases to 1.56 (95% CI = 1.39–1.76) for cerebrovascular diseases. SMR varied across cancer types, ranging from 1.14 (95% CI = 1.04–1.25) for testicular/ germ cell tumours to 2.82 (95% CI = 2.20–3.63) for brain/central nervous system tumours.  \nConclusions: Cancer survivors are at increased risk of premature CVD mortality compared to the general population, but the risk varies by cancer type and  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.  \nCVD. Future research should focus on understanding mechanisms behind the increased CVD risk to develop appropriate interventions.  \nKEYWORDS  \ncancer, cardiovascular disease, meta-analysis, standardised mortality ratios, systematic review  \n1 | INTRODUCTION  \nCardiovascular disease (CVD) and cancer are the leading causes of mortality and morbidity worldwide,1 with growing evidence that cancer survivors are at higher risk of developing CVD and have higher CVD mortality than the general population.2–4 This increased risk of CVD may be explained by shared risk factors including smoking, obesity, physical inact","cbCaig1ePWBNwqj3","https://ap.wps.com/l/cbCaig1ePWBNwqj3","pdf",286729,"English","# Abstract\n## Background\n## Objectives\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Study Rationale\n# Methodology\n## PRISMA Framework\n## Search Strategy and Selection Criteria","[{\"question\":\"What question does the systematic review address?\",\"answer\":\"It compares CVD mortality risk between people with cancer and the general population, and evaluates whether risk differs by cancer type.\"},{\"question\":\"How were eligible studies selected?\",\"answer\":\"Eligible studies included all ages with a cancer diagnosis and reported CVD mortality data as standardised mortality ratios (SMRs), were peer-reviewed, in English, and published since 2000.\"},{\"question\":\"What do the meta-analysis findings show about CVD mortality in cancer survivors?\",\"answer\":\"Cancer survivors have an increased risk of CVD death versus the general population, with pooled SMR=1.55 (95% CI 1.40–1.72). Risk varies by both CVD condition and cancer type.\"}]","Cardiovascular mortality in people with cancer compared to the general population - A systematic review and metaanalysis | PDF",1790015600,23,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/300f7b5aaf87bcbf49e81066ec236128.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/717307c1caf25b7f90e29d83557d3558.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a4085fce78e134471ad091f73cdf96cf.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2605fcda4a2284df48ca82b166b0184c.webp",980,1287]